GoAI
Get started
Concord Healthcare Grp Co Ltd logo

Concord Healthcare Grp Co Ltd

2453.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$0.875

−HK$0.01 · -1.13%

Aug 24, 4:08 PM HKT

2453.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of medical hardware and software, along with offering management and technical assistance, and providing equipment via operating leases. The company was founded in 2008 and is headquartered in Beijing, China. It functions as a subsidiary of Shanghai Medstar Financial Leasing Company.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Jianyu Yang
Listed since
Jan 9, 2024
Employees
592

Market position

Day range

Current HK$0.875

52-week range

Current HK$0.875

Open
HK$0.84
Previous close
HK$0.885
Volume
263.2K
0.66× average
Average volume
398.26K
Average daily volume
Market cap
685.7M HKD
Beta
-0.58
Market reference 1
50-day average
HK$0.7721
+13.33% above average
200-day average
HK$1.3674
-36.01% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.91B CNY
EV / EBITDA
-61.12×
Earnings yield
-21.89%
Free cash flow yield
-22.76%

Profitability & efficiency

Return on equity
-13.65%
Return on assets
-4.32%
Return on invested capital
-4.42%

Financial health

Current ratio
0.54×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends25%-47%-119%-192%Gross margin, FY2021: -19.71%Gross margin, FY2022: -41.82%Gross margin, FY2023: -12.08%Gross margin, FY2024: -17.32%Gross margin, FY2025: 6.95%Operating margin, FY2021: -83.54%Operating margin, FY2022: -101.14%Operating margin, FY2023: -65.66%Operating margin, FY2024: -95.60%Operating margin, FY2025: -51.82%Net margin, FY2021: -173.56%Net margin, FY2022: -114.66%Net margin, FY2023: -69.26%Net margin, FY2024: -114.14%Net margin, FY2025: -55.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -19.71%. Gross margin FY2022 -41.82%. Gross margin FY2023 -12.08%. Gross margin FY2024 -17.32%. Gross margin FY2025 6.95%. Operating margin FY2021 -83.54%. Operating margin FY2022 -101.14%. Operating margin FY2023 -65.66%. Operating margin FY2024 -95.60%. Operating margin FY2025 -51.82%. Net margin FY2021 -173.56%. Net margin FY2022 -114.66%. Net margin FY2023 -69.26%. Net margin FY2024 -114.14%. Net margin FY2025 -55.79%.

Income trends

Revenue

448.02M CNY+15.38%

Operating income

−232.16M CNY+37.46%

Net income

−249.96M CNY+43.60%
Income trends across reported periods674.17M CNY132.08M CNY−410.02M CNY−952.12M CNYRevenue, FY2021: 470.51M CNYRevenue, FY2022: 472.17M CNYRevenue, FY2023: 538.65M CNYRevenue, FY2024: 388.31M CNYRevenue, FY2025: 448.02M CNYOperating income, FY2021: −393.05M CNYOperating income, FY2022: −477.56M CNYOperating income, FY2023: −353.67M CNYOperating income, FY2024: −371.21M CNYOperating income, FY2025: −232.16M CNYNet income, FY2021: −816.59M CNYNet income, FY2022: −541.4M CNYNet income, FY2023: −373.09M CNYNet income, FY2024: −443.22M CNYNet income, FY2025: −249.96M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 470.51M CNY. Revenue FY2022 472.17M CNY. Revenue FY2023 538.65M CNY. Revenue FY2024 388.31M CNY. Revenue FY2025 448.02M CNY. Operating income FY2021 −393.05M CNY. Operating income FY2022 −477.56M CNY. Operating income FY2023 −353.67M CNY. Operating income FY2024 −371.21M CNY. Operating income FY2025 −232.16M CNY. Net income FY2021 −816.59M CNY. Net income FY2022 −541.4M CNY. Net income FY2023 −373.09M CNY. Net income FY2024 −443.22M CNY. Net income FY2025 −249.96M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue448.02M CNY388.31M CNY538.65M CNY472.17M CNY470.51M CNY
Cost of goods sold416.9M CNY455.55M CNY603.74M CNY746.53M CNY659.81M CNY
Gross profit31.12M CNY−67.25M CNY−65.09M CNY−197.46M CNY−92.76M CNY
Research and development27.44M CNY31.18M CNY36.44M CNY41.32M CNY40.38M CNY
Selling, general, and administrative186.58M CNY259.36M CNY252.97M CNY274M CNY102.87M CNY
Operating expenses263.29M CNY330.3M CNY288.58M CNY358.81M CNY376.27M CNY
Interest income658.5K CNY733K CNY7.28M CNY7.79M CNY5.47M CNY
Interest expense120.33M CNY109.27M CNY108.01M CNY274.48M CNY435.31M CNY
Depreciation and amortization149.13M CNY114.06M CNY152.01M CNY114.29M CNY83.79M CNY
Operating income−232.16M CNY−371.21M CNY−353.67M CNY−477.56M CNY−393.05M CNY
Net income−249.96M CNY−443.22M CNY−373.09M CNY−541.4M CNY−816.59M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.33
FY2025
Latest fiscal-year revenue
448.02M CNY
FY2025 · +15.38% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.25-0.57-0.9-1.22FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend553.68M493.55M433.41M373.27MFY21FY22FY23FY24FY25

2453.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.66

-3.20%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.42

-5.06%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.10

-5.99%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.45

-2.88%

Continue in GoAI

Research 2453.HK

research.disclaimer